Supreme Cannabis Launches Cannabis Genetics Company, Cambium Plant Sciences

Published: April 24, 2019

Supreme Cannabis Launches Cannabis Genetics Company, Cambium Plant Sciences

The Supreme Cannabis Company, Inc. announced the launch of Cambium Plant Sciences located in Goderich, Ontario. Cambium, a wholly-owned subsidiary of Supreme Cannabis, aims to lead the agricultural revolution of cannabis genetics, redefining consumer experiences and cultivation economics across the global cannabis industry. With the systematic application of research, technology and science, Cambium will focus on developing the next generation of premium cannabis genetics for recreational, medical and wellness applications. Cambium’s innovative mission is to supply agriculturally-focused, disease resistant, premium seed stock to the rapidly growing global cannabis market.

“Our proprietary genetics selection methodology and ability to cultivate high-end cannabis at scale at 7ACRES has created strong industry demand for our proprietary genetics and cultivation techniques. It was as a result of the demand that we saw a global opportunity to create a company whose sole focus is innovating plant genetics and cultivation IP for the global cannabis market. We believe genetics are the foundation of proprietary cannabis products in the long term,” said Navdeep Dhaliwal, CEO of Supreme Cannabis. “Cambium will develop cultivars that benefit our in-house brands, as well as our domestic and global cultivation and manufacturing partners. Initially, Cambium is expected to benefit from 7ACRES’ established genetics, existing infrastructure and the unparalleled plant knowledge of its team.”

Leading Cambium as General Manager is Dr. Alan Darlington. Dr. Darlington joined Supreme Cannabis’ wholly-owned subsidiary, 7ACRES as the Director of Special Projects, where he has been successful in improving the agricultural performance of 7ACRES’ award winning genetics. Dr. Darlington holds a PhD from the University of Guelph in greenhouse systems and has over 30 years of experience leading and working with diverse multidisciplinary teams to develop plant-based IP.

“Cannabis has not yet had the benefit of the agricultural revolution that transformed commercial agriculture on a global scale over the past century. We believe, Cambium will play a leading role in advancing the cannabis industry by revolutionizing strain development to enhance the broader industry’s outputs,” said Dr. Alan Darlington, General Manager of Cambium. “From the next blockbuster recreational strain, to disease resistant agricultural seed stock, Cambium will seek to improve the economic profile of cannabis production by pushing the boundaries of the cannabis plant.”

Supreme Cannabis will invest approximately $14 million to develop a world leading facility for cannabis-focused research and innovation. The Cambium facility will include the development of proprietary growing rooms for testing and selection of new genetics, breeding rooms for the creation of new seed stock, and supporting infrastructure in the existing 34,000 sqft facility. Supreme Cannabis expects to commence the retrofitting of the Cambium facility in the early summer of 2019 and Cambium has commenced the Health Canada licensing process.

Recent News

View All News Items

Latest Article

Artificial Intelligence, Learning and Explosive Growth in Cannabis

Artificial Intelligence, Learning and Explosive Growth in Cannabis

Organizations operating in the industry have a distinct need for clear communication across multiple departments and sophisticated ways of training new employees quickly to ensure compliance, efficiency and more. Companies looking to grow and capitalize need to be agile and have the ability to train employees on the latest information necessary for success.

Read Article